Suraj Bhansali

Dr. Suraj Bhansali has earned his Ph.D. in Pharmaceutics from the University at Buffalo (UB), USA and Masters in Neuro Pharmacology from South Dakota State University (SDSU), USA.

Dr. Bhansali heads the division of Clinical Pharmacology and Pharmacometrics at Excelra and works on creating clinical trial outcomes databases and data analytics solutions to support drug discovery and clinical drug development.

Before joining Excelra, Dr. Bhansali has worked at Novartis, where he was involved in clinical drug development (Phase I-IV) of biologics and small molecules including designing clinical pharmacology development strategies and leading modeling & simulation programs. He provided critical input to regulatory documents including INDs, NDA and sBLA. He has been a key contributor towards successful approval of canakinumab (Ilaris), tobramycin (TOBI Podhaler), and ribociclib (Kisqali).

His research expertise includes clinical & pre-clinical PK/PD, development of biotherapeutics and pediatric drug development and he has extensively published (authored and co-authored) 50+ research publications including original research/review articles, conference proceedings, and book chapters.

Dr. Bhansali is an Adjunct Professor at the University of New England, Portland, ME and serves as a reviewer for various peer-reviewed journals. He is a recipient of numerous awards and recognitions from the ACCP, AAPS, NBC, University of Buffalo, and Novartis Pharmaceuticals. In his free time, he loves hiking, biking and playing volleyball.